Gilead Sciences (GILD) Advances While Market Declines: Some Information for Investors

In the latest close session, Gilead Sciences (GILD) was up +1.72% at $141.95. This move outpaced the S&P 500's daily loss of 0.43%. Meanwhile, the Dow experienced a drop of 0.37%, and the technology-dominated Nasdaq saw a decrease of 0.94%. The stock of HIV and hepatitis C drugmaker has risen by 13.7% in the past month, leading the Medical sector's loss of 2.36% and the S&P 500's gain of 0.89%.The investment community will be closely monitoring the performance of Gilead Sciences in its forthcoming earnings report. The company is scheduled to release its earnings on February 10, 2026. On that day, Gilead Sciences is projected to report earnings of $1.87 per share, which would represent a year-over-year decline of 1.58%. Alongside, our most recent consensus estimate is anticipating revenue of $7.57 billion, indicating a 0.01% upward movement from the same quarter last year. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $8.15 per share and revenue of $29.07 billion, indicating changes of +76.41% and 0%, respectively, compared to the previous year. It is also important to note the recent changes to analyst estimates for Gilead Sciences. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.33% higher. Gilead Sciences currently has a Zacks Rank of #3 (Hold). Looking at valuation, Gilead Sciences is presently trading at a Forward P/E ratio of 16.23. This signifies a discount in comparison to the average Forward P/E of 20.22 for its industry. Investors should also note that GILD has a PEG ratio of 0.73 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.47 as of yesterday's close. The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 88, positioning it in the top 36% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. 5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They includeStock #1: A Disruptive Force with Notable Growth and ResilienceStock #2: Bullish Signs Signaling to Buy the DipStock #3: One of the Most Compelling Investments in the MarketStock #4: Leader In a Red-Hot Industry Poised for GrowthStock #5: Modern Omni-Channel Platform Coiled to SpringMost of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.See Our Newest 5 Stocks Set to Double Picks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks